KEQU · XBRL financial data

Kewaunee Scientific financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (KEQU's year ends in late April)

In thousands of dollars	FY 2021Apr 30, 2021	FY 2022Apr 30, 2022	FY 2023Apr 30, 2023	FY 2024Apr 30, 2024	FY 2025Apr 30, 2025	FY 2026Apr 30, 2026
Revenue from contracts with customers	147,469	168,872	219,494	203,755	240,472	281,999
Cost of goods and services sold	123,476	144,652	183,906	151,704	171,615	201,559
Gross profit	23,993	24,220	35,588	52,051	68,857	80,440
Research and development	1,406	990	1,012	920	919	898
Total operating expenses	25,309	26,828	30,224	33,770	51,098	63,725
Operating income (loss)	(1,316)	(2,608)	5,364	18,281	17,759	16,715
Interest expense	389	632	1,734	1,799	3,214	3,862
Income tax expense (benefit)	990	3,518	3,139	(5,938)	3,202	3,268
Net income (loss)	(3,672)	(6,126)	738	18,753	11,405	9,618
Earnings per share, basic USD per share	(1.33)	(2.20)	0.26	6.51	3.98	3.36
Earnings per share, diluted USD per share	(1.33)	(2.20)	0.25	6.38	3.83	3.22
Weighted average shares, basic thousands of shares	2,760	2,786	2,824	2,879	2,862	2,863
Weighted average shares, diluted thousands of shares	2,760	2,786	2,902	2,938	2,979	2,983

Fiscal years (KEQU's year ends in late April)

In thousands of dollars	FY 2021Apr 30, 2021	FY 2022Apr 30, 2022	FY 2023Apr 30, 2023	FY 2024Apr 30, 2024	FY 2025Apr 30, 2025	FY 2026Apr 30, 2026
Cash and cash equivalents	5,206	4,433	8,078	23,267	14,942	9,950
Accounts receivable	34,095	41,254	46,081	45,064	62,384	58,738
Inventory	16,517	23,796	21,889	20,679	32,849	30,533
Prepaid and other current assets	3,159	6,164	6,135	5,136	5,966	4,509
Total current assets	60,457	91,565	87,920	96,817	118,363	105,397
Property and equipment, net	15,982	15,121	16,402	17,649	23,174	22,367
Right-of-use asset	9,279	7,573	9,170	7,454	12,965	10,791
Goodwill	—	—	—	0	12,487	12,487
Total assets	89,384	118,773	118,898	134,766	194,654	178,311
Accounts payable	16,780	27,316	23,599	23,262	27,033	22,455
Current portion of long-term debt	—	—	—	—	3,000	5,000
Total current liabilities	34,181	42,293	40,053	40,780	53,712	48,351
Long-term debt	—	—	—	—	34,685	15,083
Lease liability, non-current	7,860	6,179	7,136	5,434	8,797	6,287
Total liabilities	47,897	82,593	80,413	78,557	128,409	101,499
Retained earnings	34,149	28,023	28,761	47,514	58,919	68,537
Total stockholders' equity	41,241	35,694	37,409	54,760	64,457	74,718
Total liabilities and equity	89,384	118,773	118,898	134,766	194,654	178,311
Common shares outstanding (cover page) thousands of shares	2,771	2,793	2,880	2,840	2,844	2,870

Fiscal years (KEQU's year ends in late April)

In thousands of dollars	FY 2021Apr 30, 2021	FY 2022Apr 30, 2022	FY 2023Apr 30, 2023	FY 2024Apr 30, 2024	FY 2025Apr 30, 2025	FY 2026Apr 30, 2026
Net income (loss)	(3,672)	(6,126)	738	18,753	11,405	9,618
Stock-based compensation	634	729	886	1,028	1,441	2,126
Depreciation and amortization	—	—	—	3,125	4,759	6,281
Net cash from operating activities	912	(7,885)	(3,790)	19,564	14,783	18,633
Net cash from investing activities	(2,397)	(1,908)	(4,148)	(4,373)	(30,901)	(3,937)
Share repurchases	—	—	0	1,998	1,596	0
Dividends paid	0	—	—	—	—	—
Proceeds from long-term debt	0	377	0	202	—	—
Repayments of long-term debt	19	0	121	88	—	—
Net cash from financing activities	1,982	11,031	14,931	(3,014)	7,411	(19,326)
Net change in cash	516	1,163	6,921	12,123	(8,774)	(5,547)

SIC 3821 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3821 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Kewaunee Scientific	8,246	66,320	1,976	2.9M	—	Q1 FY27 10-QJul 31, 2026
Intest	22,102	35,313	not reported	12.8M	—	Q2 FY26 10-QJun 30, 2026
Geospace Technologies	2,833	15,804	(10,688)*	12.9M	0.3 quarters	Q3 FY26 10-QJun 30, 2026
ScanTech AI Systems	158	631	(758)*	75.6M	0.2 quarters	Q3 FY25 10-QSep 30, 2025
Owlet	30,948	33,865	(92)*	29.2M	336.4 quarters	Q2 FY26 10-QJun 30, 2026
Birchtech	11,836	3,791	(2,790)*	26.3M	4.2 quarters	Q2 FY26 10-QJun 30, 2026
Crawford United	1,923	not reported	5,706*	not reported	—	Q3 FY25 10-QSep 30, 2025
Hurco Companies	52,087	47,289	3,805	6.5M	—	Q3 FY26 10-QJul 31, 2026
Rapid Micro Biosystems	14,687	8,054	(12,702)*	not reported	1.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.